Tags

Type your tag names separated by a space and hit enter

Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.
Scand J Immunol. 2006 Oct; 64(4):412-9.SJ

Abstract

4-1BB ligand (4-1BBL; CD137L) is a member of the tumour necrosis factor superfamily expressed primarily on antigen presenting cells such as B cells, macrophages and dendritic cells. Its engagement with the receptor 4-1BB (CD137) has been shown to promote T-cell activation and regulate proliferation and survival of T cells. The role of the costimulatory molecule in multiple sclerosis (MS) remains unclear. In this study, the expression of 4-1BBL and soluble 4-1BBL (s4-1BBL) protein levels were analysed in peripheral blood of MS patients. Compared with healthy controls, MS patients had an increase in both plasma s4-1BBL protein levels and expression of 4-1BBL in CD14(+) monocytes. In contrast, myelin basic protein-reactive T-cell proliferation was not found to be inhibited by the use of an anti-4-1BBL antibody. The elevated s4-1BBL protein levels in the MS patients may function as a self-regulatory mechanism of 4-1BB/4-1BBL interaction and costimulation.

Authors+Show Affiliations

Department of Neurology, Peking University People's Hospital, Beijing, China. guangzhi@public.bta.net.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16970683

Citation

Liu, G-Z, et al. "Increased Soluble 4-1BB Ligand (4-1BBL) Levels in Peripheral Blood of Patients With Multiple Sclerosis." Scandinavian Journal of Immunology, vol. 64, no. 4, 2006, pp. 412-9.
Liu GZ, Gomes AC, Putheti P, et al. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. Scand J Immunol. 2006;64(4):412-9.
Liu, G. Z., Gomes, A. C., Putheti, P., Karrenbauer, V., Kostulas, K., Press, R., Hillert, J., Hjelmström, P., & Gao, X. G. (2006). Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. Scandinavian Journal of Immunology, 64(4), 412-9.
Liu GZ, et al. Increased Soluble 4-1BB Ligand (4-1BBL) Levels in Peripheral Blood of Patients With Multiple Sclerosis. Scand J Immunol. 2006;64(4):412-9. PubMed PMID: 16970683.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis. AU - Liu,G-Z, AU - Gomes,A C, AU - Putheti,P, AU - Karrenbauer,V, AU - Kostulas,K, AU - Press,R, AU - Hillert,J, AU - Hjelmström,P, AU - Gao,X-G, PY - 2006/9/15/pubmed PY - 2006/11/1/medline PY - 2006/9/15/entrez SP - 412 EP - 9 JF - Scandinavian journal of immunology JO - Scand J Immunol VL - 64 IS - 4 N2 - 4-1BB ligand (4-1BBL; CD137L) is a member of the tumour necrosis factor superfamily expressed primarily on antigen presenting cells such as B cells, macrophages and dendritic cells. Its engagement with the receptor 4-1BB (CD137) has been shown to promote T-cell activation and regulate proliferation and survival of T cells. The role of the costimulatory molecule in multiple sclerosis (MS) remains unclear. In this study, the expression of 4-1BBL and soluble 4-1BBL (s4-1BBL) protein levels were analysed in peripheral blood of MS patients. Compared with healthy controls, MS patients had an increase in both plasma s4-1BBL protein levels and expression of 4-1BBL in CD14(+) monocytes. In contrast, myelin basic protein-reactive T-cell proliferation was not found to be inhibited by the use of an anti-4-1BBL antibody. The elevated s4-1BBL protein levels in the MS patients may function as a self-regulatory mechanism of 4-1BB/4-1BBL interaction and costimulation. SN - 0300-9475 UR - https://www.unboundmedicine.com/medline/citation/16970683/Increased_soluble_4_1BB_ligand__4_1BBL__levels_in_peripheral_blood_of_patients_with_multiple_sclerosis_ L2 - https://doi.org/10.1111/j.1365-3083.2006.01796.x DB - PRIME DP - Unbound Medicine ER -